spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  T cell therapies 

 HSMN NewsFeed - 26 Nov 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Oct 2024
AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Mar 2024
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Dec 2023
cTRL Therapeutics Appoints Ruben Rodriguez, Ph.D., as Head of Research
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Nov 2023
cTRL Therapeutics Appoints Derrell D. Porter, M.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Feb 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Dec 2022
Curate Biosciences Announces David Backer as Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 9 Aug 2022
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 May 2022
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Mar 2022
TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Feb 2022
TC Biopharm Announces Appointment of New Board Members
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Aug 2021
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Mar 2021
PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 May 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Jan 2020
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Dec 2019
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Apr 2019
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Mar 2019
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2018
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Aug 2018
SQZ Biotech Completes Oversubscribed $72 Million Series C Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 11 Jun 2018
Replimune Appoints Dr. Hyam I. Levitsky to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 May 2018
TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 30 Apr 2018
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2018
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Mar 2018
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2017
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 27 Sep 2016
Neon Therapeutics Appoints Oncology Veteran Hugh O’Dowd to Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Nov 2015
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 1 Oct 2015
Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 17 Oct 2011
Spinal Cord Injury Medical Leader Dr. Edward Wirth Joins InVivo Therapeutics as Chief Science Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
T cell therapies
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.